Prof Meyer Michel Samama, Prof Hugo ten Cate
In this Thrombosis Journal series, the greater simplicity and potential of a new class of direct-action oral anticoagulants (DOACs) is explored along with the new challenges they present.
This thematic series has not been sponsored. Articles have been invited by the journal, and have undergone the standard peer review process overseen by the Guest Editors.
MMS declares no conflict of interest. HTC, Chairman of the Dutch Foundation of Anticoagulation Services, has received fees for lectures and consultation from several industries involved in diagnostic anticoagulation tests, or the development of direct-action oral anticoagulants.